These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1397740)

  • 41. Relation between interleukin-1beta messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori.
    Wang M; Furuta T; Takashima M; Futami H; Shirai N; Hanai H; Kaneko E
    J Gastroenterol; 1999; 34 Suppl 11():10-7. PubMed ID: 10616759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized comparison of triple therapy Helicobacter pylori eradication regimens in children with peptic ulcers.
    Shcherbakov PL; Filin VA; Volkov IA; Tatarinov PA; Belousov YB
    J Int Med Res; 2001; 29(3):147-53. PubMed ID: 11471851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer.
    Nebiki H; Higuchi K; Arakawa T; Ando K; Uchida T; Ito H; Harihara S; Kuroki T; Kobayashi K
    Dig Dis Sci; 1998 Sep; 43(9 Suppl):203S-206S. PubMed ID: 9753251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
    Hu FL; Jia JC; Li YL; Yang GB
    J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease].
    Habu Y; Kiyota K; Inokuchi H; Sugano Y; Ko K; Waki S
    Nihon Rinsho; 1999 Jan; 57(1):135-9. PubMed ID: 10036950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin.
    Adamek RJ; Opferkuch W; Pfaffenbach B; Wegener M
    Am J Gastroenterol; 1996 Jan; 91(1):98-100. PubMed ID: 8561153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Helicobacter pylori and peptic ulcer.
    Korman MG; Tytgat GN
    Scand J Gastroenterol Suppl; 1995; 210():92-6. PubMed ID: 8578219
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N; Fennerty MB
    Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection.
    Kasai C; Sugimoto K; Moritani I; Tanaka J; Oya Y; Inoue H; Tameda M; Shiraki K; Ito M; Takei Y; Takase K
    BMC Gastroenterol; 2016 Oct; 16(1):119. PubMed ID: 27716077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease.
    Kullavanijaya P; Gonlachanvit S; Mahachai V; Kladchareon N
    J Med Assoc Thai; 2000 Mar; 83(3):230-5. PubMed ID: 10808676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eradication of Helicobacter pylori and its effect in peptic ulcer disease.
    Bell GD; Powell KU
    Scand J Gastroenterol Suppl; 1993; 196():7-11. PubMed ID: 8341990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum IL-8 as a possible marker for determining the status of Helicobacter pylori infection in patients with untreated and treated peptic ulcer.
    Cheng KS; Tang HL; Chou FT
    Adv Ther; 2004; 21(1):39-46. PubMed ID: 15191156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hp and pH: implications for the eradication of Helicobacter pylori.
    Hunt RH
    Scand J Gastroenterol Suppl; 1993; 196():12-6. PubMed ID: 8341986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism.
    Hunt RH
    Am J Gastroenterol; 1993 Apr; 88(4):481-3. PubMed ID: 8470623
    [No Abstract]   [Full Text] [Related]  

  • 56. pH-dependent secretion of gastrin in duodenal ulcer disease: effect of suppressing Helicobacter pylori.
    Moss SF; Playford RJ; Ayesu K; Li SK; Calam J
    Digestion; 1992; 52(3-4):173-8. PubMed ID: 1459351
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Helicobacter pylori and ulcerogenesis.
    Peura DA
    Am J Med; 1996 May; 100(5A):19S-25S; discussion 25S-26S. PubMed ID: 8644778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eradication of Helicobacter pylori restores elevation of serum gastrin concentrations in patients with end-stage renal disease.
    Tokushima H; Tamura H; Murakawa M; Matsumura O; Itakura Y; Itoyama S; Mitarai T; Isoda K
    Intern Med; 1998 May; 37(5):435-9. PubMed ID: 9652896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acid inhibitory potency of twice a day omeprazole is not affected by eradication of Helicobacter pylori in healthy volunteers.
    Thomson AB; Keelan M; Lastiwka R; Appelman-Eszcuck S; Zuk L; Drozdowski L; Prentice A; Sinclair P
    Helicobacter; 2003 Feb; 8(1):46-58. PubMed ID: 12603616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole.
    Gillen D; Wirz AA; Neithercut WD; Ardill JE; McColl KE
    Gut; 1999 Apr; 44(4):468-75. PubMed ID: 10075952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.